These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

357 related articles for article (PubMed ID: 25402380)

  • 1. The influence of combined oral contraceptives containing drospirenone on hypothalamic-pituitary-adrenocortical axis activity and glucocorticoid receptor expression and function in women with polycystic ovary syndrome.
    Macut D; Božić Antić I; Nestorov J; Topalović V; Bjekić Macut J; Panidis D; Kastratović Kotlica B; Papadakis E; Matić G; Vojnović Milutinović D
    Hormones (Athens); 2015; 14(1):109-17. PubMed ID: 25402380
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypothalamic-pituitary-adrenocortical axis hypersensitivity and glucocorticoid receptor expression and function in women with polycystic ovary syndrome.
    Milutinović DV; Macut D; Božić I; Nestorov J; Damjanović S; Matić G
    Exp Clin Endocrinol Diabetes; 2011 Nov; 119(10):636-43. PubMed ID: 22068557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of oral contraceptives on markers of hyperandrogenism and SHBG in women with polycystic ovary syndrome.
    De Leo V; Di Sabatino A; Musacchio MC; Morgante G; Scolaro V; Cianci A; Petraglia F
    Contraception; 2010 Sep; 82(3):276-80. PubMed ID: 20705157
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Body composition in lean women with polycystic ovary syndrome: effect of ethinyl estradiol and drospirenone combination.
    Aydin K; Cinar N; Aksoy DY; Bozdag G; Yildiz BO
    Contraception; 2013 Mar; 87(3):358-62. PubMed ID: 22898361
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of chlormadinone acetate versus drospirenone-containing oral contraceptives on the endocrinal features of women with polycystic ovary syndrome: Systematic review and meta-analysis of randomized clinical trials.
    Menshawy A; Ismail A; Abdel-Maboud M; El-Din AA; Elgebaly A; Gadelkarim M; Bahbah EI; Abdelghany MF; Samy A; Abbas AM
    J Gynecol Obstet Hum Reprod; 2019 Nov; 48(9):763-770. PubMed ID: 30940512
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of adrenocortical steroidogenesis in women with post-adolescent severe acne and polycystic ovary syndrome.
    Cinar N; Cetinozman F; Aksoy DY; Elcin G; Yildiz BO
    J Eur Acad Dermatol Venereol; 2015 May; 29(5):875-80. PubMed ID: 25176476
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hyperandrogenism in women with polycystic ovary syndrome persists after menopause.
    Markopoulos MC; Rizos D; Valsamakis G; Deligeoroglou E; Grigoriou O; Chrousos GP; Creatsas G; Mastorakos G
    J Clin Endocrinol Metab; 2011 Mar; 96(3):623-31. PubMed ID: 21177795
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Maintaining physiological testosterone levels by adding dehydroepiandrosterone to combined oral contraceptives: I. Endocrine effects.
    Coelingh Bennink HJT; Zimmerman Y; Laan E; Termeer HMM; Appels N; Albert A; Fauser BCJM; Thijssen JHH; van Lunsen RHW
    Contraception; 2017 Nov; 96(5):322-329. PubMed ID: 27393080
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Restoring testosterone levels by adding dehydroepiandrosterone to a drospirenone containing combined oral contraceptive: I. Endocrine effects.
    Zimmerman Y; Foidart JM; Pintiaux A; Minon JM; Fauser BC; Cobey K; Coelingh Bennink HJ
    Contraception; 2015 Feb; 91(2):127-33. PubMed ID: 25604900
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Age, body mass index, and serum level of DHEA-S can predict glucocorticoid receptor function in women with polycystic ovary syndrome.
    Macut D; Vojnović Milutinović D; Božić I; Matić G; Brkljačić J; Panidis D; Petakov M; Spanos N; Bjekić J; Stanojlović O; Petrović Milinković A; Radojičić Z; Damjanović S
    Endocrine; 2010 Feb; 37(1):129-34. PubMed ID: 20963561
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of oral contraceptive containing ethinyl estradiol combined with drospirenone vs. desogestrel on clinical and biochemical parameters in patients with polycystic ovary syndrome.
    Kriplani A; Periyasamy AJ; Agarwal N; Kulshrestha V; Kumar A; Ammini AC
    Contraception; 2010 Aug; 82(2):139-46. PubMed ID: 20654754
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ovulation after glucocorticoid suppression of adrenal androgens in the polycystic ovary syndrome is not predicted by the basal dehydroepiandrosterone sulfate level.
    Azziz R; Black VY; Knochenhauer ES; Hines GA; Boots LR
    J Clin Endocrinol Metab; 1999 Mar; 84(3):946-50. PubMed ID: 10084576
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of different antiandrogenic progestins on clinical and biochemical variables in polycystic ovary syndrome.
    Morgante G; Cappelli V; Troìa L; De Leo V
    Eur J Contracept Reprod Health Care; 2020 Jun; 25(3):176-181. PubMed ID: 32191532
    [No Abstract]   [Full Text] [Related]  

  • 14. Evidence of a disturbance of the hypothalamic-pituitary-adrenal axis in polycystic ovary syndrome: effect of naloxone.
    Lanzone A; Guido M; Ciampelli M; Fulghesu AM; Pavone V; Proto C; Caruso A; Mancuso S
    Clin Endocrinol (Oxf); 1996 Jul; 45(1):73-7. PubMed ID: 8796141
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Unique effects on hepatic function, lipid metabolism, bone and growth endocrine parameters of estetrol in combined oral contraceptives.
    Mawet M; Maillard C; Klipping C; Zimmerman Y; Foidart JM; Coelingh Bennink HJ
    Eur J Contracept Reprod Health Care; 2015; 20(6):463-75. PubMed ID: 26212489
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical, hormonal and metabolic parameters in women with PCOS with different combined oral contraceptives (containing chlormadinone acetate versus drospirenone).
    Podfigurna A; Meczekalski B; Petraglia F; Luisi S
    J Endocrinol Invest; 2020 Apr; 43(4):483-492. PubMed ID: 31654312
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of overnight dexamethasone suppression on the adrenal androgen response to an oral glucose tolerance test in women with and without polycystic ovary syndrome.
    Buyalos RP; Geffner ME; Azziz R; Judd HL
    Hum Reprod; 1997 Jun; 12(6):1138-41. PubMed ID: 9221990
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of a combined oral contraceptive containing 20 mcg of ethinylestradiol and 3 mg of drospirenone on the blood pressure, renin-angiotensin-aldosterone system, insulin resistance, and androgenic profile of healthy young women.
    Giribela CR; Consolim-Colombo FM; Nisenbaum MG; Moraes TL; Giribela AH; Baracat EC; Melo NR
    Gynecol Endocrinol; 2015; 31(11):912-5. PubMed ID: 26172927
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of drospirenone (3 mg) with ethinyl estradiol (30 mcg) containing pills on ovarian blood flows in women with polycystic ovary syndrome: a case controlled study.
    Okyay E; Gode F; Acet F; Bodur T; Cagliyan E; Sahan C; Posaci C; Gulekli B
    Eur J Obstet Gynecol Reprod Biol; 2014 Sep; 180():93-9. PubMed ID: 25063905
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined receptor antagonist stimulation of the hypothalamic-pituitary-adrenal axis test identifies impaired negative feedback sensitivity to cortisol in obese men.
    Mattsson C; Reynolds RM; Simonyte K; Olsson T; Walker BR
    J Clin Endocrinol Metab; 2009 Apr; 94(4):1347-52. PubMed ID: 19141586
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.